Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA. Genome Research. 2021. Hudecova I.*, Smith C.G.*, Hansel-Hertsch R.*, …, Mouliere F. https://genome.cshlp.org/content/early/2021/12/20/gr.275691.121.abstract

Cell-free DNA technologies for the analysis of brain cancer. British Journal of Cancer. 2021. Mair R., and Mouliere F. https://doi.org/10.1038/s41416-021-01594-5

Cell-free DNA fragmentation patterns and personalized sequencing reveal circulating tumor DNA in urine and plasma of glioma patients. EMBO Molecular Medicine. 2021. Mouliere F., Smith C.G., Heider K., Jing S., van Der Pol Y., Thompson M., Morris J., Chandrananda D., Wan J.C.M, Hudecova I., Watts C., Brindle K., Rosenfeld N., Mair R. https://doi.org/10.15252/emmm.202012881

PCR-free shallow whole genome sequencing for chromosomal copy number detection from plasma of cancer patients is an efficient alternative to the conventional PCR-based approach. Journal of Molecular Diagnostics. 2021. Beagan J., Drees E.E.E., Stahi P., Eijk P., et al. https://doi.org/10.1016/j.jmoldx.2021.08.008


Cell-free DNA fragmentomics: the new “Omics” on the block. Clinical Chemistry. 2020. Chiu R.W.K., Heitzer E., Lo Y.M.K., Mouliere F. and Tsui D.W.Y. https://doi.org/10.1093/clinchem/hvaa258

ctDNA monitoring using patient-specific sequencing and integration of variant reads. Science Translational Medicine. 2020. Wan J.C.M. et al. https://doi.org/10.1126/scitranslmed.aaz8084

Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients – initial observations. PlosOne. 2020. Ahlborn Barlebo L., et al. https://doi.org/10.1371/journal.pone.0231884

Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. Genome Medicine. 2020. Smith C.G., Moser T., Mouliere F., et al. https://doi.org/10.1186/s13073-020-00723-8


Towards the early detection of cancer by decoding the epigenetic and micro-environmental fingerprints of cell-free DNA. Cancer Cell. 2019. Van der Pol Y. and Mouliere F. https://doi.org/10.1016/j.ccell.2019.09.003


Enhanced detection of circulating tumor DNA with fragment size analysis. Science Translational Medicine. 2018. Mouliere F., Chandrananda D., Piskorz A.M., Moore L., et al. https://stm.sciencemag.org/content/10/466/eaat4921

Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients. EMBO Molecular Medicine. 2018. Mouliere F., Mair R., et al. https://doi.org/10.15252/emmm.201809323

Measurement of plasma cell-free mitochondrial tumor DNA improves detection of glioblastoma in patient-derived orthotopic xenograft models. Cancer Research. 2018. Mair R., Mouliere F., et al. https://doi.org/10.1158/0008-5472.CAN-18-0074

Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors. Oncotarget. 2018. Barlebo Ahlborn L., Villar Tuxen I., Mouliere F., et al. https://doi.org/10.18632/oncotarget.25948

The value of cell-free DNA for molecular pathology. The journal of Pathology. 2018. Stewart C., Kothari P., Mouliere F., et al. https://doi.org/10.1002/path.5048



Genome-wide cell-free DNA termini in patients with cancer. MedRxiv. 2021. Moldovan N.*, van der Pol Y.*, van den Ende T.*, Boers D., Verkuijlen S., Creemers A., Ramaker J., Vu T., Fransen M.F., Pegtel D.M., Bahce I., van Laarhoven H., Mouliere F. https://doi.org/10.1101/2021.09.30.21264176

The effect of pre-analytical and physiological variables on cell-free DNA fragmentation. BioRxiv. 2021. van der Pol Y.*, Moldovan N.*, Verkuijlen S., Ramaker J., Boers D., Onstenk W., de Rooij J., Pegtel DM, Mouliere F. https://doi.org/10.1101/2021.09.17.460828

Refined characterization of circulating tumor DNA through biological feature integration. MedRxiv. 2021. Markus H., Chandrananda D., Moore E., Mouliere F., Morris J., Brenton J., Smith C.G., Rosenfeld N. https://doi.org/10.1101/2021.08.11.21261907

Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer. MedRxiv. 2021. Crispin M., Woitek R., et al. https://doi.org/10.1101/2021.07.22.21260982

ctDNA detection by personalised assays in early-stage NSCLC. MedRxiv. 2021. Heider K., Wan J.C.M., et al. https://doi.org/10.1101/2021.06.01.21258171


Integrated clonal analysis reveals circulating tumor DNA in plasma and urine of glioma patients. BioRxiv. 2019. Mouliere F. et al. https://doi.org/10.1101/758441https://doi.org/10.1101/758441

High-sensitivity monitoring of ctDNA by patient-specific sequencing panels and integration of variant reads. BioRxiv. 2019. Wan J.C.M., Heider K., et al. https://doi.org/10.1101/759399